10.1186/2228-5326-2-33

Improved antimycobacterial activity of rifampin using solid lipid nanoparticles

Show Details XML HTML PDF
  • Ehsan Aboutaleb1,
  • Massoumeh Noori1,
  • Narges Gandomi1,
  • Fatemeh Atyabi2,
  • Mohammad Reza Fazeli3,
  • Hossein Jamalifar3,
  • Rassoul Dinarvand*4,
  1. Novel Drug Delivery Systems Laboratory, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, IR
  2. Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, IR
  3. Department of Drug and Food Control and Pharmaceutical Quality Assurance Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, IR
  4. Novel Drug Delivery Systems Laboratory, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, IR Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, IR
Cover Image

Published in Issue 2012-10-29

How to Cite

Aboutaleb, E., Noori, M., Gandomi, N., Atyabi, F., Fazeli, M. R., Jamalifar, H., & Dinarvand, R. (2012). Improved antimycobacterial activity of rifampin using solid lipid nanoparticles. International Nano Letters, 2(1 (December 2012). https://doi.org/10.1186/2228-5326-2-33
Crossref
Scopus
Google Scholar
Europe PMC

HTML views: 46

PDF views: 127

Abstract

Abstract Rifampin (RIF) is one of the front-line drugs in therapy of tuberculosis (TB). The emergence of multidrug-resistant strains of mycobacteria has greatly contributed to the increased incidence of TB. Nano-based formulation of several antimicrobials has been shown to improve either antibacterial efficacy or pharmacokinetic behavior. In this study, RIF-loaded solid lipid nanoparticles (SLNs) were prepared by a modified microemulsion-based method and their particle size, zeta potential, encapsulation efficiency, morphology, and antibacterial activity against Mycobacterium fortuitum were evaluated. The resulting SLNs were spherical with diameter of about 100 nm, with low negative zeta potential, and an encapsulation efficiency of 82%. The formulation also sustained the drug release for 72 h. The antimycobacterial efficacy was greatly improved against M. fortuitum , and the minimum inhibitory concentration of drug-loaded SLNs was eight times less than free RIF. Drug-free SLNs and the ingredients showed no antibacterial effect. It can be concluded that as expected, solid lipid nanoparticles are promising vehicles for enhanced antimycobacterial effect of rifampin.

Keywords

  • Solid lipid nanoparticles,
  • Rifampin,
  • Antibacterial activity,
  • Mycobacteria,
  • Mycobacterium fortuitum,
  • MIC,
  • Drug delivery,
  • Tuberculosis
HTML PDF

References

  1. Horsley et al. (1998) Informal care and psychiatric morbidity 20(2) (pp. 180-185) https://doi.org/10.1093/oxfordjournals.pubmed.a024740
  2. Suarez et al. (2001) Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model 18(9) (pp. 1315-1319) https://doi.org/10.1023/A:1013094112861
  3. Unknown (2009) World Health Organization
  4. Pearson et al. (1992) Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers 117(3) (pp. 191-196) https://doi.org/10.7326/0003-4819-117-3-191
  5. Zhang et al. (2010) Development of nanoparticles for antimicrobial drug delivery 17(6) (pp. 585-594) https://doi.org/10.2174/092986710790416290
  6. Mehnert and Mäder (2001) Solid lipid nanoparticles: production, characterization and applications 47(2–3) (pp. 165-196) https://doi.org/10.1016/S0169-409X(01)00105-3
  7. Müller et al. (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art 50(1) (pp. 161-177) https://doi.org/10.1016/S0939-6411(00)00087-4
  8. Müller et al. (1995) Solid lipid nanoparticles (SLN)—an alternative colloidal carrier system for controlled drug delivery (pp. 62-69)
  9. Schwarz et al. (1994) Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization 30(1) (pp. 83-96) https://doi.org/10.1016/0168-3659(94)90047-7
  10. Wissing et al. (2004) Solid lipid nanoparticles for parenteral drug delivery 56(9) (pp. 1257-1272) https://doi.org/10.1016/j.addr.2003.12.002
  11. Seth (2008) Elsevier
  12. De Rossi et al. (2006) Role of mycobacterial efflux transporters in drug resistance: an unresolved question 30(1) (pp. 36-52) https://doi.org/10.1111/j.1574-6976.2005.00002.x
  13. Briones et al. (2008) Delivery systems to increase the selectivity of antibiotics in phagocytic cells 125(3) (pp. 210-227) https://doi.org/10.1016/j.jconrel.2007.10.027
  14. Durán et al. (2008) Microencapsulation of antibiotic rifampicin in poly(3-hydroxybutyrate-co-3-hydroxyvalerate) 31(11) (pp. 1509-1516) https://doi.org/10.1007/s12272-001-2137-7
  15. Esmaeili et al. (2007) Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles 3(2) (pp. 161-167) https://doi.org/10.1016/j.nano.2007.03.003
  16. Saraogi et al. (2010) Gelatin nanocarriers as potential vectors for effective management of tuberculosis 385(1–2) (pp. 143-149) https://doi.org/10.1016/j.ijpharm.2009.10.004
  17. Skidan et al. (2003) Enhanced activity of rifampicin loaded with polybutyl cyanoacrylate nanoparticles in relation to intracellularly localized bacteria 48(1) (pp. 23-26)
  18. Pandey et al. (2003) Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis 83(6) (pp. 373-378) https://doi.org/10.1016/j.tube.2003.07.001
  19. Pandey et al. (2005) Oral solid lipid nanoparticle-based antitubercular chemotherapy 85(5–6) (pp. 415-420) https://doi.org/10.1016/j.tube.2005.08.009
  20. Bargoni et al. (2001) Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II—tissue distribution 43(5) (pp. 497-502) https://doi.org/10.1006/phrs.2001.0813
  21. Erokhina and Aleksandrova (2006) In vitro development of rifampicin resistance in the epithelial cells (pp. 58-61)
  22. Harrison (2003) Treatment of tuberculosis (pp. 1-36) Ministry of Health
  23. Kaur et al. (2008) Potential of solid lipid nanoparticles in brain targeting 127(2) (pp. 97-109) https://doi.org/10.1016/j.jconrel.2007.12.018
  24. Pandey and Khuller (2005) Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis 85(4) (pp. 227-234) https://doi.org/10.1016/j.tube.2004.11.003
  25. Gelperina et al. (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis 172(12) (pp. 1487-1490) https://doi.org/10.1164/rccm.200504-613PP
  26. Üner and Yener (2007) Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives 2(3) (pp. 289-300)
  27. Maldiney et al. (2011) Effect of core diameter, surface coating, and PEG chain length on the biodistribution of persistent luminescence nanoparticles in mice 5(2) (pp. 854-862) https://doi.org/10.1021/nn101937h
  28. Freitas and Müller (1999) Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase 47(2) (pp. 125-132) https://doi.org/10.1016/S0939-6411(98)00074-5
  29. Lim and Kim (2002) Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid 243(1–2) (pp. 135-146) https://doi.org/10.1016/S0378-5173(02)00269-7
  30. Ugazio et al. (2002) Incorporation of cyclosporin A in solid lipid nanoparticles (SLN) 241(2) (pp. 341-344) https://doi.org/10.1016/S0378-5173(02)00268-5
  31. Cavalli et al. (1996) Effects of some experimental factors on the production process of solid lipid nanoparticles (pp. 110-115)
  32. Gasco (1997) Solid lipid nanospheres from warm microemulsions 9(11) (pp. 52-58)
  33. Cavalli et al. (1998) The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules (pp. 392-396)